<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diroximel fumarate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diroximel fumarate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Diroximel fumarate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="123110" href="/d/html/123110.html" rel="external">see "Diroximel fumarate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53898963"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vumerity</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53797798"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Fumaric Acid Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F53847782"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>Safety: </b>In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]). <b>Premedication: </b>May administer aspirin (nonenteric coated ≤325 mg) 30 minutes prior to diroximel fumarate to reduce the incidence or severity of flushing.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800e2fc1-5444-4538-baf2-520898316bf7">Multiple sclerosis, relapsing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 231 mg twice daily; after 7 days, increase to the maintenance dose of 462 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F53847784"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe impairment: Use not recommended due to increase in 2-hydroxyethyl succinimide exposure.</p></div>
<div class="block doha drugH1Div" id="F53847785"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment prior to treatment initiation: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatoxicity during treatment: Discontinue treatment if diroximel fumarate–induced hepatic injury is suspected.</p></div>
<div class="block dot drugH1Div" id="F53847786"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Side effects with maintenance dose:</b> If maintenance dose is not tolerated, consider temporary dose reduction to 231 mg twice daily; resume recommended maintenance dose of 462 mg twice daily within 4 weeks. Consider discontinuation in patients who cannot tolerate return to the maintenance dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>GI reactions, severe (hemorrhage, obstruction, perforation, ulceration):</b> Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphopenia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Lymphocytes &lt;500/mm<sup>3</sup> persisting &gt;6 months: Consider therapy interruption; once resolved, base the decision to restart therapy on individual clinical circumstances.</p>
<p style="text-indent:-2em;margin-left:4em;">Infection, serious: Consider therapy interruption; once resolved, base the decision to restart therapy on individual clinical circumstances.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Progressive multifocal leukoencephalopathy:</b> If progressive multifocal leukoencephalopathy (PML) is suspected, withhold therapy immediately and perform a diagnostic evaluation; permanently discontinue if PML is confirmed.</p></div>
<div class="block doe drugH1Div" id="F53847783"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F53898994"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. All adverse reactions were reported in adults with dimethyl fumarate delayed-release capsules, which have the same active metabolite as diroximel fumarate.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (18%), diarrhea (14%), nausea (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (60%; similar to placebo; including aspergillosis, candidiasis, cytomegalovirus disease, herpes meningoencephalitis, herpes simplex infection, herpes zoster infection [including disseminated, meningomyelitis, or ophthalmicus], listeriosis, nocardiosis, opportunistic infection [including West Nile], tuberculosis)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (5%), pruritus (8%), skin rash (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (5%), vomiting (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytopenia (2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Progressive multifocal leukoencephalopathy</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hematologic &amp; oncologic: Eosinophilia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury, increased serum bilirubin (&gt;2 x ULN), increased serum transaminases (≥3 x ULN)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinorrhea</p></div>
<div class="block coi drugH1Div" id="F53797801"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, angioedema) to diroximel fumarate, dimethyl fumarate, or to any component of the formulation; concomitant use of dimethyl fumarate.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F53847767"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Flushing: Dimethyl fumarate, which has the same active metabolite as diroximel fumarate, commonly causes mild to moderate flushing (eg, warmth, redness, itching, burning sensation); flushing generally appears soon after initiation, and improves or resolves with subsequent dosing. Administration with food may decrease flushing incidence. Administration of aspirin (nonenteric coated ≤325 mg) 30 minutes prior to diroximel fumarate may also reduce the incidence or severity of flushing.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI events: GI events (eg, diarrhea, nausea, upper abdominal pain, vomiting, constipation) commonly occur with dimethyl fumarate, which has the same active metabolite as diroximel fumarate. GI events generally occur in the first month of use and decrease thereafter. Severe GI reactions (eg, hemorrhage, obstruction, perforation, ulceration) occurring within 6 months (majority) of treatment initiation and with or without concomitant aspirin use have also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Clinically significant postmarketing cases of hepatic injury have been reported with dimethyl fumarate, which has the same active metabolite as diroximel fumarate. Onset has ranged from a few days to several months after treatment initiation. Signs/symptoms of hepatic injury, including transaminase elevations &gt;5 times ULN and total bilirubin elevations &gt;2 times ULN have been observed with dimethyl fumarate. Some cases have required hospitalization; however, none of the cases were fatal or resulted in liver failure or transplant. LFT abnormalities resolved upon discontinuation. Drug-induced hepatocellular injury resulting in new-onset transaminase elevations combined with increased bilirubin levels is an important predictor of serious hepatic injury that may lead to acute hepatic failure, liver transplant, or death in some patients. Transaminase elevations (usually &lt;3 times ULN) were observed in dimethyl fumarate clinical trials, generally occurring in the first 6 months of treatment. Transaminase elevations ≥3 times ULN occurred rarely. Monitor LFTs; discontinue treatment if diroximel fumarate–induced hepatic injury is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Anaphylaxis and angioedema may occur after the first dose or at any time during treatment. Discontinue therapy if signs and symptoms of anaphylaxis or angioedema occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Serious cases of herpes zoster (eg, disseminated, ophthalmicus, meningoencephalitis, meningomyelitis) have been reported with dimethyl fumarate, which has the same active metabolite as diroximel fumarate; may develop any time during treatment. Other serious opportunistic infections have occurred with dimethyl fumarate, including viral (eg, <i>Cytomegalovirus</i>, herpes simplex, West Nile), fungal (eg, <i>Aspergillus</i>, <i>Candida</i>), and bacterial (eg, <i>Listeria monocytogenes</i>, <i>Mycobacterium tuberculosis</i>, <i>Nocardia</i>), in patients with and without lymphopenia. Consider temporary interruption of therapy until infection has resolved. In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Lymphopenia: Decreased lymphocyte counts may occur. The risk for lymphopenia is not reduced over time with dimethyl fumarate, which has the same active metabolite as diroximel fumarate. In patients receiving dimethyl fumarate with prolonged, severe lymphopenia (eg, lymphocytes &lt;500 cells/mm<sup>3</sup> for ≥6 months), the median time for lymphocyte counts to return to normal after discontinuation of therapy was 96 weeks; in patients with nonprolonged, mild to severe lymphopenia, the median time to return to normal after discontinuation of therapy ranged from 4 to 16.7 weeks, based on lymphopenia severity during treatment. Obtain a CBC, including lymphocyte count, prior to initiation of therapy, then every 3 to 6 months thereafter, and as clinically indicated (AAN [Rae-Grant 2018]; EMA 2015). Monitor for signs of infection in patients with lower lymphocyte counts at baseline and mild to moderate lymphopenia (Baharnoori 2018). Consider therapy interruption in patients with lymphocyte counts &lt;500/mm<sup>3</sup> persisting &gt;6 months and in patients with serious infections. Progressive multifocal leukoencephalopathy (PML) may occur in patients with a lymphocyte count &lt;500/mm<sup>3</sup> for &lt;6 months (Lehmann-Horn 2016). Due to a potential for delayed lymphocyte recovery following treatment interruption or discontinuation, monitor lymphocyte counts until lymphopenia is resolved. The decision to restart diroximel fumarate should be individualized based on clinical circumstances. Neither diroximel fumarate nor dimethyl fumarate have been studied in patients with preexisting low lymphocyte counts.</p>
<p style="text-indent:-2em;margin-left:4em;">• Progressive multifocal leukoencephalopathy: Cases of progressive multifocal leukoencephalopathy (PML) due to the John Cunningham (JC) virus, including fatality, have occurred with dimethyl fumarate, which has the same active metabolite as diroximel fumarate. Risk factors for development of PML include HIV, AIDS, cancer history, rheumatologic disease history, persistent lymphocytopenia, sarcoidosis, and prior immunosuppressant use (Jamilloux 2014; Tan 2010). However, cases of PML have been reported with dimethyl fumarate use in patients who were not immunocompromised and had no prior exposure to immunosuppressive drugs, including natalizumab. Severe, long-standing lymphopenia was identified as a primary risk for PML, and the majority of PML cases occurred in patients with lymphocyte counts &lt;500/mm<sup>3</sup> (although the exact role of lymphopenia in PML is unknown). At the first sign or symptom suggestive of PML, withhold therapy immediately and perform a diagnostic evaluation; symptoms progress over days to weeks and may include progressive weakness on one side of the body or clumsiness of limbs, vision disturbances, and changes in mental status. Cases of PML have been diagnosed based on MRI findings and the detection of JC virus DNA in the cerebral spinal fluid without specific PML signs/symptoms. Monitoring with brain MRI for signs that may be consistent with PML may be beneficial and allow for an early diagnosis of PML (EMA 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Avoid live-attenuated vaccines in patients who currently receive or have recently discontinued diroximel fumarate; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]).</p></div>
<div class="block foc drugH1Div" id="F53898964"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vumerity: 231 mg [contains carrageenan]</p></div>
<div class="block geq drugH1Div" id="F53898962"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53986096"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Vumerity Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">231 mg (per each): $86.33</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F53847788"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food. If administered with food, limit fat and calories to ≤30 g and ≤700 calories, respectively. Swallow capsule whole; do not crush, chew, or open.</p></div>
<div class="block use drugH1Div" id="F53797800"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Multiple sclerosis, relapsing:</b> Treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.</p></div>
<div class="block cyt drugH1Div" id="F53848662"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53848659"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May decrease serum concentrations of the active metabolite(s) of Diroximel Fumarate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethyl Fumarate: May enhance the adverse/toxic effect of Diroximel Fumarate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monomethyl Fumarate: May enhance the adverse/toxic effect of Diroximel Fumarate.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F53847769"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">A high-fat (&gt;30 g), high-calorie (&gt;700 calories) meal may significantly decrease the maximum concentration of the major active metabolite, monomethyl fumarate (MMF). Alcohol decreases peak MMF plasma concentration when coadministered with diroximel fumarate. Management: Take diroximel fumarate with or without food. If taken with food, limit fat and calories to ≤30 g and ≤700 calories, respectively. Avoid alcohol at the same time a dose of diroximel fumarate is taken.</p></div>
<div class="block rep_considerations drugH1Div" id="F53847765"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">In general, disease-modifying therapies for multiple sclerosis are stopped prior to a planned pregnancy, except in females at high risk of multiple sclerosis activity (AAN [Rae-Grant 2018]). Consider use of agents other than diroximel fumarate for females at high risk of disease reactivation who are planning a pregnancy. Delaying pregnancy is recommended for females with persistent high disease activity; when disease-modifying therapy is needed in these patients, other agents are preferred (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block pri drugH1Div" id="F53847764"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in some animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis are not initiated during pregnancy, except in females at high risk of multiple sclerosis activity (AAN [Rae-Grant 2018]). When disease-modifying therapy is needed in these patients, other agents are preferred (ECTRIMS/ EAN [Montalban 2018]).</p></div>
<div class="block brc drugH1Div" id="F53847766"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if diroximel fumarate or its active metabolite monomethyl fumarate are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F53847787"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May administer with or without food. If taken with food, limit fat and calories to ≤30 g and ≤700 calories, respectively. Avoid alcohol at the same time a dose of diroximel fumarate is taken.</p></div>
<div class="block mop drugH1Div" id="F53847790"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, including lymphocytes (prior to initiation of therapy, then every 3 to 6 months thereafter, or as clinically indicated) (AAN [Rae-Grant 2018]; EMA 2015); LFT, including transaminases, alkaline phosphatase, total bilirubin (baseline and during treatment as clinically indicated); MRI (baseline and as clinically indicated to monitor for early signs of progressive multifocal leukoencephalopathy [PML]); latent infection screening (eg, hepatitis, tuberculosis) in high-risk populations or in countries with high tuberculosis burden (baseline); signs/symptoms of severe GI reactions, hypersensitivity, infections, and/or PML.</p></div>
<div class="block pha drugH1Div" id="F53847771"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Diroximel fumarate and its active metabolite, monomethyl fumarate (MMF), have been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, which is involved in cellular response to oxidative stress. The mechanism by which diroximel fumarate exerts a therapeutic effect in multiple sclerosis is unknown, although it is believed to result from its anti-inflammatory and cytoprotective properties via activation of the Nrf2 pathway (Fox 2012; Gold 2012). MMF has also been identified as a nicotinic acid receptor agonist in vitro.</p></div>
<div class="block phk drugH1Div" id="F53847772"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Diroximel fumarate is not quantifiable in plasma following oral administration due to extensive presystemic metabolism. All pharmacokinetic data are based on monomethyl fumarate (MMF) (major active metabolite), unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 72 to 83 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 27% to 45%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Diroximel fumarate undergoes rapid and extensive presystemic hydrolysis by esterases to MMF (major active metabolite) and 2-hydroxyethyl succinimide (inactive major metabolite). MMF is further metabolized via the tricarboxylic acid cycle, with no involvement of the cytochrome P450 (CYP-450) system.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2.5 to 3 hours (fasting), 4.5 hours (with a 350 to 700 calorie and 10 to 30 g fat meal); 7 hours (with a &gt;700 calorie and &gt;30 g fat meal).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;0.3%); expired air (as carbon dioxide).</p></div>
<div class="block phksp drugH1Div" id="F53847780"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: 2-hydroxyethyl succinimide exposure increased by 1.3-, 1.8-, and 2.7-fold in patients with mild, moderate, and severe renal impairment, respectively, compared to healthy patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56521941"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Vumerity</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29304497">
<a name="29304497"></a>Baharnoori M, Gonzalez CT, Chua A, et al. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. <i>Mult Scler Relat Disord</i>. 2018;20:51-57. doi: 10.1016/j.msard.2017.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diroximel-fumarate-drug-information/abstract-text/29304497/pubmed" id="29304497" target="_blank">29304497</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  European Medicines Agency (EMA). Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera. Published October 23, 2015. Accessed November 11, 2019. https://www.ema.europa.eu/en/documents/press-release/updated-recommendations-minimise-risk-rare-brain-infection-pml-tecfidera_en.pdf
                  </div>
</li>
<li>
<div class="reference">
                  Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diroximel-fumarate-drug-information/abstract-text/31462584/pubmed" id="31462584" target="_blank">31462584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22992072">
<a name="22992072"></a>Fox RJ, Miller DH, Phillips JT, et al; CONFIRM Study Investigators. Placebo-controlled phase 3 Study of oral BG-12 or glatiramer in multiple sclerosis [published correction appears in <i>N Engl J Med</i>. 2012;367(17):1673]. <i>N Engl J Med.</i> 2012;367(12):1087-1097. doi: 10.1056/NEJMoa1206328<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diroximel-fumarate-drug-information/abstract-text/22992072/pubmed" id="22992072" target="_blank">22992072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22992073">
<a name="22992073"></a>Gold R, Kappos L, Arnold DL, et al; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis [published correction appears in <i>N Engl J Med</i>. 2012;367(24):2362]. <i>N Engl J Med.</i> 2012;367(12):1098-1107. doi: 10.1056/NEJMoa1114287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diroximel-fumarate-drug-information/abstract-text/22992073/pubmed" id="22992073" target="_blank">22992073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24610328">
<a name="24610328"></a>Jamilloux Y, Néel A, Lecouffe-Desprets M, et al. Progressive multifocal leukoencephalopathy in patients with sarcoidosis. <i>Neurology</i>. 2014;82(15):1307-1313. doi: 10.1212/WNL.0000000000000318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diroximel-fumarate-drug-information/abstract-text/24610328/pubmed" id="24610328" target="_blank">24610328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27343070">
<a name="27343070"></a>Lehmann-Horn K, Penkert H, Grein P, et al. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter? <i>Neurology</i>. 2016;87(4):440-441. doi: 10.1212/WNL.0000000000002900<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diroximel-fumarate-drug-information/abstract-text/27343070/pubmed" id="27343070" target="_blank">27343070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352526">
<a name="29352526"></a>Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis [published correction appears in <i>Eur J Neurol</i>. 2018;25(3):605].<i> Eur J Neurol</i>. 2018;25(2):215-237. doi: 10.1111/ene.13536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diroximel-fumarate-drug-information/abstract-text/29352526/pubmed" id="29352526" target="_blank">29352526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29686116">
<a name="29686116"></a>Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology [published correction appears in <i>Neurology</i>. 2019;92(2):112]. <i>Neurology</i>. 2018;90(17):777-788. doi: 10.1212/WNL.0000000000005347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diroximel-fumarate-drug-information/abstract-text/29686116/pubmed" id="29686116" target="_blank">29686116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20298966">
<a name="20298966"></a>Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. <i>Lancet Neurol</i>. 2010;9(4):425-437. doi: 10.1016/S1474-4422(10)70040-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diroximel-fumarate-drug-information/abstract-text/20298966/pubmed" id="20298966" target="_blank">20298966</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vumerity (diroximel fumarate) [prescribing information]. Cambridge, MA: Biogen Inc; December 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 123109 Version 52.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
